Cynata Therapeutics Limited Stock Probability of Future Pink Sheet Price Finishing Under 0.19
| CYYNF Stock | USD 0.19 0.00 0.00% |
Cynata |
Cynata Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Cynata Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Cynata Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Cynata Therapeutics generated a negative expected return over the last 90 days | |
| Cynata Therapeutics has some characteristics of a very speculative penny stock | |
| Cynata Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 7.77 M. Net Loss for the year was (5.45 M) with profit before overhead, payroll, taxes, and interest of 7.77 M. | |
| Cynata Therapeutics Limited has accumulated about 26.79 M in cash with (3.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.19. | |
| Roughly 15.0% of the company shares are held by company insiders |
Cynata Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Cynata Pink Sheet often depends not only on the future outlook of the current and potential Cynata Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Cynata Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 143.3 M |
Cynata Therapeutics Technical Analysis
Cynata Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Cynata Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Cynata Therapeutics Limited. In general, you should focus on analyzing Cynata Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Cynata Therapeutics Predictive Forecast Models
Cynata Therapeutics' time-series forecasting models is one of many Cynata Therapeutics' pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Cynata Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Cynata Therapeutics
Checking the ongoing alerts about Cynata Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Cynata Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Cynata Therapeutics generated a negative expected return over the last 90 days | |
| Cynata Therapeutics has some characteristics of a very speculative penny stock | |
| Cynata Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 7.77 M. Net Loss for the year was (5.45 M) with profit before overhead, payroll, taxes, and interest of 7.77 M. | |
| Cynata Therapeutics Limited has accumulated about 26.79 M in cash with (3.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.19. | |
| Roughly 15.0% of the company shares are held by company insiders |
Other Information on Investing in Cynata Pink Sheet
Cynata Therapeutics financial ratios help investors to determine whether Cynata Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cynata with respect to the benefits of owning Cynata Therapeutics security.